Shaf joined Recursion in early 2020 after 16 plus years of experience in life science. He served most recently as the chief executive officer of Navire Pharma and CoA Therapeutics, which are two subsidiaries at BridgeBio Pharma. Prior to that, he served as Global Head of neuroscience, ophthalmology and rare disease partnering at Roche/Genentech, where he helped build an industry-leading pipeline via licensing and M&A.
In 13 years at Roche, he held various roles of increasing importance within medical affairs, marketing and business development in the U.K., U.S. and Switzerland. Shaf conducts pharmaceutical business and clinical development as the chief corporate development officer, in addition to leading the internal development of Recursion’s clinical-stage assets as the chief executive officer of its Development Corporation, a wholly-owned unit of Recursion.
Shaf was trained as a neurosurgeon in Cambridge, U.K. and Boston, and holds the Fellowship of the Royal College of Surgeons of England, in addition to a medical degree from the University of Nottingham. He spends his free time with family, playing tennis and reading about early Exploration in Africa